Drug Action
Ezetimibe inhibits the intestinal absorption of cholesterol. If used alone, it has a modest effect on lowering LDL-cholesterol, with little effect on other lipoproteins.
PDF page 232
Loading InternPractice…
Drug reference
Ezetimibe inhibits the intestinal absorption of cholesterol. If used alone, it has a modest effect on lowering LDL-cholesterol, with little effect on other lipoproteins.
PDF page 232
Adjunct to dietary measures and statin treatment in primary hypercholesterolaemia | Adjunct to dietary measures and statin in homozygous familial hypercholesterolaemia | Primary hypercholesterolaemia (if statin inappropriate or not tolerated) | Adjunct to dietary measures in homozygous sitosterolaemia ▶BY MOUTH ▶Adult: 10 mg daily
PDF page 232
NICE decisions ▶Ezetimibe for treating primary heterozygous-familial and non- familial hypercholesterolaemia (February 2016) NICE TA385 This guidance should be used with NICE’s guidelines on cardiovascular disease: risk assessment and reduction, including lipid modification and familial hypercholesterolaemia: identification and management (see, Cardiovascular disease risk assessment and prevention p. 201 and Dyslipidaemias p. 208). Ezetimibe, alone, is recommended as an option for the treatment of primary (heterozygous-familial or non- familial) hypercholesterolaemia in adults in whom initial statin therapy is contra-indicated, or who are intolerant of initial statin therapy. Ezetimibe, in combination with initial statin therapy, is also recommended as an option for the treatment of primary (heterozygous-familial or non-familial) hypercholesterolaemia in adults when: . serum total or low-density lipoprotein (LDL) cholesterol concentration is not appropriately controlled either after appropriate dose titration of initial statin therapy or because dose titration is limited by intolerance to the initial statin therapy, and . a change from initial statin therapy to an alternative statin is being considered. When prescribing ezetimibe in combination with a statin, ezetimibe should be prescribed on the basis of lowest acquisition cost. www.nice.org.uk/guidance/ta385
PDF pages 232, 233
→Appendix 1: ezetimibe
PDF page 232
▶Common or very common Asthenia. diarrhoea. gastrointestinal discomfort. gastrointestinal disorders ▶Uncommon Appetite decreased. arthralgia. chest pain. cough. hot flush. hypertension. muscle complaints. nausea. pain ▶Frequency not known Constipation. depression. dizziness. dyspnoea. hepatitis. myopathy. pancreatitis. paraesthesia. skin reactions. thrombocytopenia
PDF page 232
Manufacturer advises use only if potential benefit outweighs risk—no information available.
PDF page 232
Manufacturer advises avoid—present in milk in animal studies.
PDF page 232
Manufacturer advises avoid in moderate to severe impairment.
PDF page 232
There can be variation in the licensing of different medicines containing the same drug. Tablet ▶Ezetimibe (Non-proprietary) Ezetimibe 10 mg Ezetimibe 10mg tablets | 28 tablet P £26.31 DT = £1.65 ▶Ezetrol (Merck Sharp & Dohme Ltd) Ezetimibe 10 mg Ezetrol 10mg tablets | 28 tablet P £26.31 DT = £1.65 Combinations available: Simvastatin with ezetimibe, p. 218 LIPID MODIFYING DRUGS › FIBRATES
PDF page 233
10 mg daily
First-line fragment. Read the complete Indications and Dose section above.
PDF page 232